USPTO serial 99195259
VALERIS
Reviewed by CopyMark Law Group
Status 688Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- LIU, PHILIP
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with VALERIS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $2,143*
Plus Government fees of $1,050
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Jeffersonville, IN, US
Jeffersonville, DE, US
JEFFERSONVILLE, IN, US
Jeffersonville, DE, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Larry L. Coats
Larry L. Coats Coats & Bennett, PLLC1400 Crescent GreenSuite 300Cary, NC 27518Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | downloadable podcasts for educational purposes in the field of disease, pharmaceutical brands, and affordable healthcare options | ACTIVE | — |
| 035 | Business management and administration of pharmacy reimbursement programs; Administering the distribution of prescription pharmaceutical samples, namely, prescription pharmaceutical sample distribution to physicians and patients; Mail-order pharmacy services; Business management and administration of patient co-pay reimbursement programs; Business management and administration of financial assistance programs that provide patients with access to affordable medicine, namely business management and administration of enrollment and reimbursement programs for the purchase of medication; Business management and administration of pharmaceutical patient support programs, namely, programs that facilitate patient enrollment, insurance benefit verification, reimbursement support, prior authorization processing, copay assistance, patient financial assistance, and medication adherence support for patients receiving prescription pharmaceutical therapies; Business management and administration of patient engagement programs; Business management and administration of formulary, patient, and payer policy information; Business management and administration of educational engagements for health care providers, namely, business management and administration of healthcare provider educational outreach programs relating to pharmaceutical products, disease states and standards of care; Management of the distribution of clinical trial medication and supplies, namely, coordinating the delivery of such medication and supplies to clinical trial sites; Providing business marketing information regarding tracking pharmaceutical promotional programs and evaluating and determining their effectiveness; Business data management services in the field of pharmaceutical patient safety, namely, collection and compilation of information into computer database and preparation of business reports for business and regulatory compliance purposes; Outbound healthcare provider engagement services provided, namely, promoting public awareness of diseases, pharmaceutical brands, and treatment affordable options; Outbound healthcare provider engagement services, namely, marketing services in the nature of promotion of pharmaceutical manufacturers disease treatment options via social media; Providing business information in the field of tracking payer coverage policies with regards to pharmaceutical reimbursement, co-pay assistance, and patient affordability in order to enhance their market access strategies and patient support programs; Life science business strategy consulting services for assisting clients with commercial assessments, corporate and portfolio strategy, new product planning and commercialization support, and pricing and market access insights; Business assistance management and information services regarding enrolling patients of pharmaceutical manufacturers into support programs that enable patients to view, track, and manage the support program wherein the patient support program provides pharmaceutical consumer product information, payer coverage status updates, and providing business information regarding access to enrollment and reimbursement programs for the purchase of medications; Providing business information in the pharmaceutical and life science industries concerning developments in the field of co-pay assistance and patient affordability programs; the foregoing services offered to or provided on behalf of pharmaceutical and life sciences companies | ACTIVE | — |
| 036 | Payment services, namely, reimbursement payment processing in the field of pharmaceutical financial assistance claims as a part of a program and loyalty program payment processing services provided on behalf of pharmaceutical manufacturers for the purpose of delivering benefits to patients enrolled in pharmaceutical manufacturer-sponsored financial assistance programs | ACTIVE | — |
| 041 | Outbound healthcare provider engagement services provided on behalf of pharmaceutical manufacturers, namely, providing online non-downloadable podcasts, seminars, workshops, and virtual and in-person presentations for educational purposes in the field of diseases, pharmaceutical brands, and affordable healthcare options; Educational services, namely, conducting seminars and workshops in the fields of drug therapy, side effect management, lifestyle management, disease state management and proper administration of medication; Educational services, namely, providing training programs in the field of clinical support relating to drug therapy, side effect management, disease state management and proper administration of medication | ACTIVE | — |
| 042 | Providing quality assurance in the field of patient claims and quality control patient claim services for others for monitoring paid claims to patients from insurance or pharmaceutical entities to insure that specific business rules are being correctly applied to patient claims; Pharmacovigilance services for others, namely, scientific research and analysis in the nature of pharmaceutical product evaluation pertaining to adverse events and product quality complaints regarding pharmaceutical products, assessment of risks presented by certain pharmaceutical products or combinations thereof, and product safety testing and consultation related thereto in the field of pharmaceuticals; Pharmacovigilance services for others, namely, monitoring efficacy of pharmaceutical preparations for quality control purposes; Providing online non-downloadable software for patient support by enrolling patients of pharmaceutical manufacturers in support programs that enables the patients to view, track and manage the support program wherein the patient support program provides pharmaceutical product and medication education, medication adherence support, visibility into medication delivery and case status, injection and product educational training, access to financial assistance programs, payer coverage status updates, patient reminders and notifications; Data warehousing services; Database development services for the purpose of collecting and maintaining patient information and registry data; Database development services, for the purpose of customized data collection and maintaining related databases in the field of prescription drugs; Software as a service (SAAS) services, namely, hosting software for use by others for managing pharmaceutical drug inventory, billing and account receivables, shipping and reporting pharmaceutical drug inventory, aggregating and analyzing patient data for the purpose of connecting clinical programs with specialty drug manufacturers and call centers; Developing customized software for others for managing pharmaceutical drug inventory, billing and account receivables, shipping and reporting pharmaceutical drug inventory, aggregating and analyzing patient data for the purpose of connecting clinical programs with specialty drug manufacturers and call centers; Electronic monitoring for the pharmaceutical industry of insurance co-pay cards to detect fraud via the internet for assuring that patients who have full or partial federally funded drug coverage are excluded from utilizing co-pay cards | ACTIVE | — |
| 044 | Medical counseling in the field of drug therapy, side effect management, disease state management and proper administration of medication; Pharmaceutical consultation in the field of new specialty drugs; providing information to patients regarding the administration of prescription medications as a part of patient support programs offered on behalf of pharmaceutical manufacturers; Patient health care counseling and advice regarding products in the field of prescription drugs; providing online medical information regarding prescription medications as a part of patient support programs offered on behalf of pharmaceutical manufacturers; Specialty pharmacy services in the nature of pharmaceutical advice and dispensing of pharmaceuticals | ACTIVE | — |
| 045 | Pharmacy benefit fraud monitoring, namely, investigation services related to pharmacy benefit insurance claims; Personal lifestyle consulting services; Providing patient advocate and case management services, namely, coordinating the procurement and administration of medication; Providing emotional counseling and emotional support services for medical patients | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Phantom Purchaser, Inc.
- Other trademarks owned by Phantom Purchaser, Inc.
- Other trademarks owned by VALERIS, INC.
- Other trademarks owned by Phantom Purchaser, Inc.
- Other trademarks in Class 009
- Other trademarks in Class 035
- Other trademarks in Class 036
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Similar marks named VALERIS
- Prosecution event EISU explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 14, 2026 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Oct 6, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Aug 11, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 11, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 5, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 16, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 16, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 16, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 16, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 16, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 8, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 8, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 8, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 8, 2026 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Jun 30, 2026 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Jun 12, 2026 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Jun 4, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jun 4, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 4, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 4, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jun 4, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 3, 2026 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Jun 3, 2026 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Apr 21, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 21, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 21, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 22, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 22, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 22, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 21, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 20, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 17, 2025 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| May 21, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 21, 2025 | NWAP | NEW APPLICATION ENTERED | — |